Abstract
A clinical study of a long-acting oral steroid formulation, containing 2.0 mg quinestrol and 2.5 mg quingestanol acetate, was undertaken during a 31-month period. A total of 212 women were enrolled in the study and 2,781 women-months experience was accumulated. Life-table analysis of event rates at the end of 1 year revealed the event rates for discontinuation to be 7.3 for pregnancy, 11.2 for abnormal bleeding and 17.3 for other medical reasons. The cumulative continuation rate at the end of 1 year was only 46.9, indicating this method was not well accepted in this population group.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
